Table 3.

Clinical studies of c-Met targeting therapy in urologic neoplasms.

Conditions	Interventions	First Posted	Number Enrolled	Phase	NCT (Number)	State	Status
RCC	foretinib	June 30, 2006	74	Phase 2	NCT00726323	United States	Completed
Papillary Renal Cell Cancer	AZD6094	April 30, 2014	111	Phase 2	NCT02127710	United States	Completed
RCC	APL-101/Nivolumab	September 5, 2018	20	Phase 1 Phase 2	NCT03655613	Australia	Terminated
RCC	INC280/bevacizumab	September 22, 2015	65	Phase 1	NCT02386826	United States	Active, not recruiting
Papillary RCC	Savolitinib/durvalumab/sunitinib	October 28, 2021	220	Phase 3	NCT05043090	United States	Recruiting
Advanced RCC	Drug: APL-101 Oral Capsules	September 27, 2017	344	Phase 1 Phase 2	NCT03175224	United States	Recruiting
Recurrent RCC	Erlotinib/Tivantinib	August 20, 2012	55	Phase 2	NCT01688973	United States	Completed
Advanced Solid Tumors	Axitinib/crizotinib	February 26, 2014	50	Phase 1	NCT01999972	United States	Completed
Advanced RCC Metastatic RCC	Cabozantinib	May 14, 2018	445	Phase 2	NCT03428217	United States	Completed
RCC	Cabozantinib	June 2013	658	Phase 3	NCT01865747	United States	Completed
Renal Clear Cell Carcinoma Renal Papillary Cell Carcinoma	Savolitinib/MEDI4736/Tremelimumab	January 2017	181	Phase 2	NCT02819596	United Kingdom	Active, not recruiting
Solid Tumors	INC280	February 29, 2012	131	Phase 1	NCT01324479	United States	Completed
Advanced Solid Tumors	Treatment with ARQ 197 in combination with sorafenib	September 2009	87	Phase 1	NCT00827177	United States	Completed
CRPC	Crizotinib/Enzalutamide	August 2014	24	Phase 1	NCT02207504	United States	Completed
CRPC	Tivantinib	January 11, 2012	78	Phase 2	NCT01519414	United States	Completed
PCa	Savolitinib/Durvalumab/Tremelimumab	December 12, 2017	500	Phase 2	NCT03385655	Canada	Recruiting
Urinary Bladder Neoplasms Ureteral Neoplasms Urethral Neoplasms	Crizotinib	September 27, 2016	8	Phase 2	NCT02612194	United States	Terminated

All clinicaltrials can be downloaded from www.clinicaltrials.gov (accessed October 5, 2022).